Healthcare Industry News: MEVION S250
News Release - May 6, 2015
RaySearch Laboratories: First Proton Treatments with RayStation and MEVION S250Ackerman Cancer Center in Jacksonville, Florida treats its first patient with the MEVION S250 and the RayStation® Treatment Planning System
STOCKHOLM--(Healthcare Sales & Marketing Network)--On April 30, 2015 a major milestone was reached at Ackerman Cancer Center in Jacksonville, Florida when the first patient was treated with the MEVION S250 and the RayStation® Treatment Planning System. Ackerman Cancer Center is the first private, physician-owned practice to implement proton therapy.
The clinical patient treatment plans were created entirely in RayStation®, RaySearch’s highly advanced treatment planning and dose tracking software platform, and delivered on the MEVION S250 Proton System. “Providing this kind of innovative technology in a private setting is something that we knew we could accomplish. We look forward to working with our partners, RaySearch and Mevion, well into the future to bring cutting edge treatments to our patients,” said Scot Ackerman, M.D., Medical Director of the Center.
“The implementation of proton therapy in a private center really shows how far this technology has come and how accessible it can be,” says Marc Mlyn, President of RaySearch Americas, Inc. “We are pleased that the Mevion and RaySearch combined solution has led to such a successful effort so rapidly, and we are glad to be partners with Ackerman Cancer Center’s team of professionals.”
“While we have many clinical proton sites in the USA, Europe and soon Asia, it is very satisfying to see the first Mevion and RaySearch effort up and running. RayStation was developed to handle any type of delivery system, and we will continue to work in close collaboration with our partners to bring new and exciting technologies to our mutual customers”, says Johan Löf, CEO of RaySearch Laboratories AB.
The current version of RayStation® supports all relevant proton treatment techniques such as Uniform Scanning, Double Scattering and PBS / IMPT.
About Ackerman Cancer Center
Ackerman Cancer Center’s mission is to deliver the highest quality personalized cancer care while remaining committed to the mission of service to those in need throughout the entire spectrum of society. In addition to providing the most advanced radiation oncology treatment available, Ackerman Cancer Center is focused on improving cancer outcomes and quality of life for patients in a compassionate and respectful environment. A highly trained staff of Radiation Oncologists and medical professionals provide convenient access of care at three locations across Northeast Florida. For more information, please visit www.AckermanCancerCenter.com.
RayStation® integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch provides the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading partners such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched via partners and RaySearch’s software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.
For more information about RaySearch, please visit www.raysearchlabs.com
Source: RaySearch Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.